Myriad Genetics (MYGN) Shares Outstanding (Weighted Average) (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Shares Outstanding (Weighted Average) data on file, last reported at $93.7 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $93.7 million, up 2.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.7 million (up 2.52% YoY), and the FY2025 annual result was $92.6 million, up 2.21% from the prior year.
• Shares Outstanding (Weighted Average) improved to $93.7 million in Q1 2026 per MYGN's latest filing, from $92.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $93.7 million in Q1 2026 and troughed at $80.1 million in Q1 2022.
• A 5-year average of $86.7 million and a median of $89.9 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) climbed 1.12% in 2023, then gained 10.91% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $80.6 million in 2022, then climbed by 2.73% to $82.8 million in 2023, then grew by 9.42% to $90.6 million in 2024, then gained by 2.21% to $92.6 million in 2025, then increased by 1.19% to $93.7 million in 2026.
• Business Quant data shows MYGN's Shares Outstanding (Weighted Average) at $93.7 million in Q1 2026, $92.6 million in Q4 2025, and $92.3 million in Q3 2025.